Works in Diabetes, Obesity & Metabolism, 2023, Vol 25, Issue 12


Results: 44
    1

    Front Cover.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. C1, doi. 10.1111/dom.15371
    By:
    • Yabe, Daisuke;
    • Shiki, Kosuke;
    • Homma, Gosuke;
    • Meinicke, Thomas;
    • Ogura, Yuji;
    • Seino, Yutaka
    Publication type:
    Article
    2
    3
    4

    Long‐term effects of coronavirus disease 2019 on diabetes complications and mortality in people with diabetes: Two cohorts in the UK and Hong Kong.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3807, doi. 10.1111/dom.15279
    By:
    • Wan, Eric Yuk Fai;
    • Mathur, Sukriti;
    • Zhang, Ran;
    • Lam, Athene Hoi Ying;
    • Wang, Boyuan;
    • Yan, Vincent Ka Chun;
    • Chui, Celine Sze Ling;
    • Li, Xue;
    • Wong, Carlos King Ho;
    • Lai, Francisco Tsz Tsun;
    • Cheung, Ching Lung;
    • Chan, Esther Wai Yin;
    • Tan, Kathryn Choon Beng;
    • Wong, Ian Chi Kei
    Publication type:
    Article
    5
    6
    7
    8
    9

    A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3788, doi. 10.1111/dom.15274
    By:
    • Ji, Linong;
    • Lu, Jinmiao;
    • Gao, Leili;
    • Yan, Xiaoguang;
    • Li, Jifang;
    • Cheng, Zhifeng;
    • Zhang, Lili;
    • Tian, Junhang;
    • Li, Ping;
    • Bai, Jie;
    • Xie, Daosheng;
    • Zhao, Jiahong;
    • Ding, Juping;
    • Yu, Qiang;
    • Wang, Tong
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    Younger patients and low c‐peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium‐glucose cotransporter 2 inhibitor administration.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3682, doi. 10.1111/dom.15262
    By:
    • Nakajima, Hanako;
    • Okada, Hiroshi;
    • Yoshimura, Yuta;
    • Tanaka, Toru;
    • Hasegawa, Goji;
    • Mitsuhashi, Kazuteru;
    • Kitagawa, Noriyuki;
    • Okamura, Takuro;
    • Hashimoto, Yoshitaka;
    • Senmaru, Takafumi;
    • Ushigome, Emi;
    • Nakanishi, Naoko;
    • Yamazaki, Masahiro;
    • Hamaguchi, Masahide;
    • Fukui, Michiaki
    Publication type:
    Article
    22
    23

    Diabetes foot complications and standardized mortality rate in type 2 diabetes.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3662, doi. 10.1111/dom.15260
    By:
    • Stedman, Mike;
    • Robinson, Adam;
    • Dunn, George;
    • Meza‐Torres, Bernado;
    • Gibson, J. Martin;
    • Reeves, Neil D.;
    • Jude, Edward B.;
    • Feher, Michael;
    • Rayman, Gerry;
    • Whyte, Martin B.;
    • Edmonds, Michael;
    • Heald, Adrian H.
    Publication type:
    Article
    24
    25

    Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial (COMING study)

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3632, doi. 10.1111/dom.15258
    By:
    • Kimura, Tomohiko;
    • Katakura, Yukino;
    • Shimoda, Masashi;
    • Kawasaki, Fumiko;
    • Yamabe, Mizuho;
    • Tatsumi, Fuminori;
    • Matsuki, Michihiro;
    • Iwamoto, Yuichiro;
    • Anno, Takatoshi;
    • Fushimi, Yoshiro;
    • Kamei, Shinji;
    • Kimura, Yukiko;
    • Nakanishi, Shuhei;
    • Mune, Tomoatsu;
    • Kaku, Kohei;
    • Kaneto, Hideaki
    Publication type:
    Article
    26
    27

    No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3621, doi. 10.1111/dom.15257
    By:
    • Rajeev, Surya Panicker;
    • Roberts, Carl Alexander;
    • Brown, Emily;
    • Sprung, Victoria S.;
    • Harrold, Jo A.;
    • Halford, Jason C. G.;
    • Stancak, Andrej;
    • Boyland, Emma J.;
    • Kemp, Graham J.;
    • Perry, Julie;
    • Howarth, Elaine;
    • Jackson, Richard;
    • Wiemken, Andrew;
    • Schwab, Richard;
    • Cuthbertson, Daniel J.;
    • Wilding, John P. H.
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34

    Beta‐cell death and dysfunction drives hyperglycaemia in organ donors.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3529, doi. 10.1111/dom.15248
    By:
    • Shapey, Iestyn M.;
    • Summers, Angela;
    • O'Sullivan, James;
    • Fullwood, Catherine;
    • Hanley, Neil A.;
    • Casey, John;
    • Forbes, Shareen;
    • Rosenthal, Miranda;
    • Johnson, Paul R. V.;
    • Choudhary, Pratik;
    • Bushnell, James;
    • Shaw, James A. M.;
    • Neiman, Daniel;
    • Shemer, Ruth;
    • Glaser, Benjamin;
    • Dor, Yuval;
    • Augustine, Titus;
    • Rutter, Martin K.;
    • van Dellen, David
    Publication type:
    Article
    35

    Impact of patient characteristic factors on the dynamics of liver glucose metabolism: Evaluation of multiparametric imaging with dynamic whole‐body <sup>18</sup>F‐fluorodeoxyglucose‐positron emission tomography.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3521, doi. 10.1111/dom.15247
    By:
    • Tonda, Kai;
    • Iwabuchi, Yu;
    • Shiga, Tohru;
    • Owaki, Yoshiki;
    • Fujita, Arashi;
    • Nakahara, Takehiro;
    • Sakurai, Ryosuke;
    • Shimizu, Atsushi;
    • Yamada, Yoshitake;
    • Okada, Masahiro;
    • Jinzaki, Masahiro
    Publication type:
    Article
    36
    37
    38

    The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3465, doi. 10.1111/dom.15244
    By:
    • Giorgino, Francesco;
    • Guerci, Bruno;
    • Füchtenbusch, Martin;
    • Lebrec, Jérémie;
    • Boye, Kristina;
    • Orsini Federici, Marco;
    • Heitmann, Elke;
    • Dib, Anne;
    • Yu, Maria;
    • Sapin, Hélène;
    • García‐Pérez, Luis‐Emilio
    Publication type:
    Article
    39
    40
    41
    42
    43

    The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3453, doi. 10.1111/dom.15145
    By:
    • Boye, Kristina S.;
    • Lebrec, Jérémie;
    • Dib, Anne;
    • Heitmann, Elke;
    • Federici, Marco Orsini;
    • Yu, Maria;
    • Sapin, Hélène;
    • Barrett, Annabel;
    • Guerci, Bruno;
    • Giorgino, Francesco;
    • Füchtenbusch, Martin;
    • García‐Pérez, Luis‐Emilio
    Publication type:
    Article
    44